Researching Economical Adjuvants to Cancer Therapy
Florida State University
60 participants
Nov 12, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to learn if beta-glucan (a dietary fiber) improves the function of the immune system in adults. It will also tell the investigators if combining beta-glucan with single bouts of exercise provides additional benefit. The main questions it aims to answer are: 1. Does beta-glucan change the ability of immune cells to recognize cancer cells? 2. Does exercise change the type of immune cells in the blood? Researchers will compare beta-glucan to a placebo (a look-alike substance with no effect) to see if beta-glucan could improve immune function against cancer. Participants will: 1. Take beta-glucan or a placebo daily for 4 weeks. 2. Visit the laboratory for three exercise tests. 3. Provide blood samples so researchers can study immune system cells.
Eligibility
Inclusion Criteria1
- Physically fit enough to engage in maximal exercise.
Exclusion Criteria14
- BMI > 40 kg/m2
- Stage 2 hypertension (140/90 mmHg)
- Type I or II diabetes
- Autoimmune diseases
- Overt cardiovascular, respiratory, or neurological disease (e.g., previous heart attack, pacemaker, heart failure, asthma)
- Hormone replacement therapy (e.g., androgens, estrogens)
- Daily medication usage that may affect immune function (e.g., beta blockers, NSAIDs, corticosteroids, allergy medications)
- Current antibiotic use
- Heavy alcohol usage (>2 drinks per day)
- Tobacco use within the last 6 months
- Adults unable to consent
- Individuals who are not yet adults (infants, children, teenagers)
- Self-reported pregnancy
- Prisoners
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
375mg of beta-glucan in the form of a ground mushroom powder. The supplement is provided in capsule form.
375mg of microcrystalline cellulose in capsule form.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07305259